Neurocrine Biosciences Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
August 1, 2018 7:16 AM EDTNeedham & Company raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $125.00 (from $110.00) while maintaining a Buy rating.
Analyst Alan Carr commented, "Neurocrine reported $96.9M in 2Q18 Ingrezza sales, above our $85.0M and consensus $84M ests. Mgmt still not providing sales guidance, but... More
Neurocrine Bio. (NBIX) PT Raised to $131 at Baird
August 1, 2018 6:58 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
